The active ingredient of a pharmaceutical drug is called an active pharmaceutical ingredient. HPAPI are compounds used to treat diseases such as cancer, hormonal imbalances, respiratory disorders, among others. High performance active pharmaceutical ingredients (HPAPI) are the fastest growing segment of the active ingredient market. Advances in clinical pharmacology and oncology research are some of the main reasons driving the growth of the HPAPI market.
An increasing geriatric population across the globe coupled with lifestyle related diseases in the younger generation are factors that are causing an increase in cancer, diabetes, cardiovascular diseases, among others. In the case of cancer, current treatment methods such as chemotherapy have severe side effects as well as they affect the non cancerous cells. Favorable government regulations are also helping with development of the pipeline of efficient drugs which is further augmenting the HPAPI market. The fact that some of the drugs are approaching patent expiry also positively impacts the market.
The High Performance Active Pharmaceutical Ingredients Market market can be segmented on the basis of type of ingredient as:
The High Performance Active Pharmaceutical Ingredients market can be segmented on the basis of type of drugs as:
Currently, oncology accounts for the largest share of the application market for HPAPI. Rising instances in hormonal imbalance in the femal population is a factor that makes this segment the second largest segment of the overall HPAPI market.
In terms of applications, the High Performance Active Pharmaceutical Ingredients Market has been segmented across the following:
North America currently accounts for the largest share of the HPAPI market while the asia pacific region is expected to grow at the fastest rate till the end of the forecast period considered in this report. Emerging economies in the APAC region are witnessing a rapid growth and development in the healthcare industry owing to increasing awareness levels and spending capacity of people in those countries.
The market has been segmented based on the following geographies:
- North America
- South America
- Middle East
Sample companies are profiled in this report are:
- Sanofi Aventis
- Hospira Inc
- Lonza Group
- BASF AG
- Bristol-Myers Squibb Company
1. High Performance Active Pharmaceutical Ingredients – Market Overview
2. Executive Summary
3. High Performance Active Pharmaceutical Ingredients– Market Landscape
3.1. Market Share Analysis
3.2. Comparative Analysis
3.2.1. Product Benchmarking
3.2.2. End User Profiling
3.2.3. Top 5 Financials Analysis
4. High Performance Active Pharmaceutical Ingredients– Market Forces
4.1. Market Drivers
4.2. Market Constraints
4.3. Market Challenges
4.4. Attractiveness of the High Performance Active Pharmaceutical Ingredients Market
4.4.1. Power of Suppliers
4.4.2. Power of Customers
4.4.3. Threat of New Entrants
4.4.4. Threat of Substitution
4.4.5. Degree of Competition
5. High Performance Active Pharmaceutical Ingredients Market– Strategic Analysis
5.1. Value Chain Analysis
5.2. Pricing Analysis
5.3. Opportunities Analysis
5.4. Product/Market Life Cycle Analysis
5.5. Suppliers and Distributors
6. High Performance Active Pharmaceutical Ingredients Market – By Type of Ingredient
7. High Performance Active Pharmaceutical Ingredients Market – By Type of Drug
8. High Performance Active Pharmaceutical Ingredients Market– By Application
9. High Performance Active Pharmaceutical Ingredients Market– By Geography
9.2. Global Study
9.3.1. North America
10. High Performance Active Pharmaceutical Ingredients Market– Market Entropy
10.1. New Product Launches
10.2. M&As, Collaborations, JVs and Partnerships
11. Company Profiles
11.1. Bristol-Myers Squibb Company
11.2. Novartis International AG
11.3. Sanofi Aventis
11.4. Pfizer Inc.
11.5. Lonza Group
11.7. Hospira Inc.
11.8. BASF AG
11.9. Merck & Co., Inc.
11.10. Sigma Aldrich Corporation
11.11. Bayer AG
11.12. Boehringer Ingelheim GmbH
11.14. Teva Pharmaceuticals Industries Ltd.
*More than 10 Companies are profiled in this Research Report*
"*Financials would be provided on a best efforts basis for private companies"
12.3. Research Methodology
12.5. Compilation of Expert Insights